Summary:
The IO360º summit presents an annual debate on hot topics within the immuno-oncology space. For the 2024 summit, they debated over the next-generation approaches that might solve some of the biggest challenges in immuno-oncology.
More specifically, our participants debate:
- Whether cell therapy or bispecific engagers were the better option for treatment, toxicity and persistence
- Which IO therapies (for example, in vivo CAR T therapy) will lead to the next big step change for the IO landscape
- Which therapies will ultimately be the most successful in solid tumors
- Combination therapies (including PD-1 and T cell engagers), and more
For more information on the upcoming IO360º Summit 2025, visit io360summit.com
Moderators
Alex Snyder, MD
Head of R&D
Generate Biomedicines
Michael Kalos, PhD
Managing Director
Next Pillar Consulting
Charles Drake, MD, PhD
VP, Immuno-Oncology
J&J Innovative Medicine
Panelists
Naiyer Rizvi, MD
CMO
Synthekine
Axel Hoos, MD, PhD
Former CEO
Scorpion Therapeutics
Kristen Hege, MD
Independent Board Member
Adaptimmune, Mersana & Graphite Bio
Speakers
William Ho, MBA
President & CEO
IN8Bio
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.